| |

There will likely never be a Lyme vaccine says researcher Alan Barbour.

Why some strains of Lyme disease bacteria are common and others are not

Findings could lead to novel strategy to control disease

New clues about the bacteria that cause Lyme disease could lead to a novel strategy to reduce infections, according to a study to be published in mBio®, the online open-access journal of the American Society for Microbiology, on December 4. The study reveals that the immune system of the white-footed mouse, a very common reservoir for Borrelia burgdorferi (the bacterium that causes the disease), responds differently to different strains of the bacterium, a finding that will help scientists tweak the animals’ immune systems to prevent infection. A vaccine that keeps these wild mice free of the pathogen could significantly curb the spread of the disease from mice to ticks to humans.

“There’s no human vaccine, and there’s not likely to be one,” says Alan Barbour of the University of California, Irvine, the lead author of the study. “We have to focus on lowering the risk. One way to do that is by treating the animals that carry the disease.” Rabies offers a good example of how this might be accomplished, says Barbour. By deploying vaccine-laced food bait, public health officials have managed to lower the rabies infection rate in wildlife and significantly limited the spread of the disease to pets and humans.

Although Lyme disease only emerged in the U.S. in the past 40 years or so, around 25,000 cases are now reported every year in this country and the medical costs of these cases are estimated to range in the billions of dollars. Despite the growing importance of the disease, little is known about the evolution and ecology of the bacterium that causes the illness.

Barbour and his colleagues sought to understand why as many as 15 different strains of B. burgdorferi exist in the wild at differing degrees of prevalence. In the parts of the country where Lyme disease is most common, the majority of white-footed mice are infected with B. burgdorferi during the course of the year. Unlike humans and lab mice, white-footed mice don’t get sick when they’re infected so the bacteria grow and multiply within them, and when a deer tick bites it sucks up the bacteria along with its blood meal.

In the lab, the group at UC Irvine exposed white-footed mice to various strains of B. burgdorferi and tracked the course of the infection. All the B. burgdorferi strains infected the white-footed mice, but some strains managed to grow to high densities in various mouse tissues while others did not.

Barbour says the immune reactions the mice mounted against the various strains explain these discrepancies: the greater the immune response, the fewer bacteria found in a mouse’s tissues and vice-versa. Importantly, the strains that grew to greatest densities within the mice are also the strains that are most prevalent in the wild.

When they looked at the immune reaction to individual B. burgdorferi proteins the authors found a complex interplay of reactivities. The mice reacted in different degrees to the various proteins present in a single bacterial strain, which could explain why such a great diversity of B. burgdorferi strains are sustained in the wild, say the authors.

Barbour says knowing more about how the white-footed mouse reacts to all the various B. burgdorferi strains and immunogenic proteins will help vaccine developers select the best proteins to put in a vaccine. “The best candidate for the mouse vaccine is something that’s the same in all the [B. burgdorferi] strains,” he says.

Once a vaccine for the white-footed mouse is developed, it will need to be tested by exposing immunized mice to a selected set of diverse B. burgdorferi strains, says Barbour, and the results of this study can help make that selection. “If we can find five that are representative, that would be an advantage.”

This study, he says, “is going to provide a foundation for future studies in understanding the infection in these animals as we proceed with developing vaccines.”

Read full paper

 

Stay safe in the outdoors

Your support can change lives

Get our news and updates by email

Similar Posts

2 Comments

  1. Article states there will probably never be a vaccine, but also states that study will provide foundation “as we proceed with developing vaccines.” Huh? What am I missing, or is it merely duplicity by someone who has massive number of Lyme disease vaccine patents, and likely ever more with each isolate discovered by his laboratory?

  2. I agree it is very ambiguous, but an interesting admission, finally. He left the door open for more funding for continued research.

    Here is another statement that may be a significant admission,

    “Barbour says the immune reactions the mice mounted against the various strains explain these discrepancies: the greater the immune response, the fewer bacteria found in a mouse’s tissues and vice-versa. Importantly, the strains that grew to greatest densities within the mice are also the strains that are most prevalent in the wild”

    This may explain what we at CanLyme see regularly, the sickest people with Lyme symptoms are the least likely to test positive using just antibody testing alone (they have a higher bacterial load which suppresses the immune response, or species/strains not used in current antibody tests).

Comments are closed.